Kinnate Biopharma Inc. Quarterly Liabilities in USD from Q4 2021 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
Summary
Kinnate Biopharma Inc. quarterly Liabilities history and growth rate from Q4 2021 to Q4 2023.
  • Kinnate Biopharma Inc. Liabilities for the quarter ending December 31, 2023 was $14.3M, a 29.9% decline year-over-year.
Liabilities, Quarterly (USD)
Liabilities, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $14.3M -$6.08M -29.9% Dec 31, 2023 10-K 2024-03-28
Q3 2023 $18.3M -$503K -2.68% Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $18.5M +$3.35M +22.1% Jun 30, 2023 10-Q 2023-08-08
Q1 2023 $21.1M +$3.32M +18.6% Mar 31, 2023 10-Q 2023-05-11
Q4 2022 $20.4M +$7.97M +64.4% Dec 31, 2022 10-K 2024-03-28
Q3 2022 $18.8M Sep 30, 2022 10-Q 2022-11-10
Q2 2022 $15.2M Jun 30, 2022 10-Q 2022-08-11
Q1 2022 $17.8M Mar 31, 2022 10-Q 2022-05-12
Q4 2021 $12.4M Dec 31, 2021 10-K 2023-03-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.